Practical radiation oncology 2024 Jul 15
Target Volume Optimization for Localized Prostate Cancer.
Abstract
Historically, the treatment of prostate cancer has required little anatomic information beyond the location of the prostate gland and adjacent seminal vesicles. Radiation therapy has classically been prescribed to the whole prostate due to the high frequency of multifocal cancer in surgical specimens and the inability to localize the precise boundaries of individual tumor foci on imaging. The development of prostate magnetic resonance imaging (MRI) and positron emission tomography (PET) using prostate-specific radiotracers has ushered in an era in which radiation oncologists are able to localize and focally dose-escalate high-risk volumes in the prostate gland. Recent phase III data have demonstrated that incorporating focal dose escalation improves biochemical control without significantly increasing toxicity. However, many questions remain regarding the optimal target volume definition and prescription strategy to implement this practice. In this review we summarize the currently available literature on image-based focal target delineation with MRI and PET. Our review includes a summary of the available data on anatomic patterns of spread to inform clinical judgement for the definition of clinical target volumes. Key knowledge gaps are identified and suggestions for novel implementation strategies are provided.
Related Questions
How do you manage prostatic adenocarcinoma after a subtotal resection?
This is a complex question with many permutations, and a review of the operative note in addition to the surgical pathology can help to inform clinical decision-making. Direct discussion with the surgeon, when possible, is also important because presumably there is some reason this occurred, which m...
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
In the situation wherein you found something on PSMA PET that wasn’t seen on MRI, I would obtain a biopsy for 2 reasons: 1. In order to confirm the presence of distant metastasis or 2. If tissue is needed for genomic testing. Otherwise, I would not biopsy in the case of discordant imaging, since I w...
What urethral dose constraints would you use off-trial for reirradiating the prostate using SBRT?
The short answer to this question is that there is no evidence-based answer. Below is a review for anyone interested. Background: The recognition of local recurrence as a pattern of failure seems to be growing, perhaps in part due to the increased utilization of advanced imaging (as previously discu...
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
Some reports do profile the use of a sequential tumor boost (e.g., Miralbell et al., PMID 19910135); however, I would usually not recommend this unless a brachytherapy boost is planned. Although I could think of a few niche circumstances where there could be a rationale for a sequential boost (SEQ),...
Under what circumstances would you treat prostate cancer without a biopsy?
I largely agree with Dr. @Dr. First Last's comments as well as a prior post on this site in which anecdotes are cited of situations which falsely appeared suggestive of prostate cancer. As contemporary guidelines recommend treatment only in patients with localized prostate cancer with > 5-10 year li...
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
At this point in time, I don't think there is a good answer to this question. The CHHiP trial, which led to the adoption of the 60 Gy in 3 Gy fraction schedule, did not have a dose constraint for the urethra. The FLAME trial, which demonstrated safety and efficacy for an SIB to a dominant intraprost...
Would you offer focal prostate boost per FLAME protocol for GTV defined by PET alone without MRI?
I think there are two questions here: Can you use PSMA PET to define the boost target? Yes (with a little bit of caution). There have been several reports on the safety/feasibility of PSMA-based focal boost. Note, though, that FLAME was based on MRI, and we can expect that the PET-defined lesion may...